B. Lipsky, A. Berendt, H. Deery, J. Embil, W. Joseph et al., Diagnosis and Treatment of Diabetic Foot Infections, Clinical Infectious Diseases, vol.39, issue.7, pp.885-910, 2004.
DOI : 10.1086/424846

F. Game and W. Jeffcoate, MRSA and osteomyelitis of the foot in diabetes, Diabetic Medicine, vol.20, issue.s4, pp.16-25, 2004.
DOI : 10.1055/s-2001-18655

N. Tentolouris, G. Petrikkos, N. Vallianou, C. Zachos, G. Daikos et al., Prevalence of methicillin-resistant Staphylococcus aureus in infected and uninfected diabetic foot ulcers, Clinical Microbiology and Infection, vol.12, issue.2, pp.186-195, 2006.
DOI : 10.1111/j.1469-0691.2005.01279.x

I. Chopra, P. Hawkey, and M. Hinton, Tetracyclines, molecular and clinical aspects, Journal of Antimicrobial Chemotherapy, vol.29, issue.3, pp.245-77, 1992.
DOI : 10.1093/jac/29.3.245
URL : http://jac.oxfordjournals.org/cgi/content/short/29/3/245

T. Doan, H. Fung, D. Mehta, and P. Riska, Tigecycline: A glycylcycline antimicrobial agent, Clinical Therapeutics, vol.28, issue.8, pp.1079-106, 2006.
DOI : 10.1016/j.clinthera.2006.08.011

M. Souli, F. Kontopidou, E. Koratzanis, A. Antoniadou, E. Giannitsioti et al., In Vitro Activity of Tigecycline against Multiple-Drug-Resistant, Including Pan-Resistant, Gram-Negative and Gram-Positive Clinical Isolates from Greek Hospitals, Antimicrobial Agents and Chemotherapy, vol.50, issue.9, pp.3166-3175, 2006.
DOI : 10.1128/AAC.00322-06

K. Waites, L. Duffy, and M. Dowzicky, Antimicrobial Susceptibility among Pathogens Collected from Hospitalized Patients in the United States and In Vitro Activity of Tigecycline, a New Glycylcycline Antimicrobial, Antimicrobial Agents and Chemotherapy, vol.50, issue.10, pp.3479-84, 2006.
DOI : 10.1128/AAC.00210-06

L. Lavery, D. Armstrong, D. Murdoch, E. Peters, and B. Lipsky, Validation of the Infectious Diseases Society of America's Diabetic Foot Infection Classification System, Clinical Infectious Diseases, vol.44, issue.4, pp.562-567, 2007.
DOI : 10.1086/511036

V. Jarlier, M. Nicolas, G. Fournier, and A. Philippon, Extended Broad-Spectrum ??-Lactamases Conferring Transferable Resistance to Newer ??-Lactam Agents in Enterobacteriaceae: Hospital Prevalence and Susceptibility Patterns, Clinical Infectious Diseases, vol.10, issue.4, pp.867-78, 1988.
DOI : 10.1093/clinids/10.4.867

C. Dean, M. Visalli, S. Projan, P. Sum, and P. Bradford, Efflux-Mediated Resistance to Tigecycline (GAR-936) in Pseudomonas aeruginosa PAO1, Antimicrobial Agents and Chemotherapy, vol.47, issue.3, pp.972-980, 2003.
DOI : 10.1128/AAC.47.3.972-978.2003

M. Visalli, E. Murphy, S. Projan, and P. Bradford, AcrAB Multidrug Efflux Pump Is Associated with Reduced Levels of Susceptibility to Tigecycline (GAR-936) in Proteus mirabilis, Antimicrobial Agents and Chemotherapy, vol.47, issue.2, pp.665-674, 2003.
DOI : 10.1128/AAC.47.2.665-669.2003

P. Bradford, D. Weaver-sands, and P. Petersen, In Vitro Activity of Tigecycline against Isolates from Patients Enrolled in Phase 3 Clinical Trials of Treatment for Complicated Skin and Skin???Structure Infections and Complicated Intra???Abdominal Infections, Clinical Infectious Diseases, vol.41, issue.s5, pp.315-347, 2005.
DOI : 10.1086/431673